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Abstract: Necrosis is an in vivo chaotic event distinguished by uncontrolled disintegration of the cell 
membrane leading to cytolysis, inflammation and tissue destruction followed by a healing or regener-
ating process. Targeting necrosis may offer potential diagnostic, therapeutic and/or theragnostic appli-
cations in translational medicine. This article reviews the current concept of necrosis including defini-
tion, etiology and pathophysiology. The evolution and development of a wide diversity of necrosis tar-
geting agents and their potential applications in preclinical and clinical settings are also elaborated and 
discussed.  
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1. INTRODUCTION 
Necrosis has been described as the fortuitous death of 
cells in a living being having subjected to severe exogenous 
or endogenous insults [1]. It has been regarded as a passive 
process of irreversible changes in membrane permeability, 
organelle breakdown and release of intracellular contents 
into the extracellular space, which in turn triggers subsequent 
inflammation and tissue healing [2].  
Identifying necrosis by imaging modalities has attracted 
attention for the management of cardiac pathologies of espe-
cially ischemic heart disease. The development of effective 
agents specific for necrosis and/or ischemia has been a de-
sired goal. In magnetic resonance imaging (MRI), a variety 
of contrast agents, most of which are based on low molecular 
weight gadolinium complexes, have been used in clinic [3]. 
However, inability to distinguish different types of patholo-
gies and a lack of specificity for necrosis has been noted. 
Categories of porphyrin and non-porphyrin compounds with 
highly selective, affinity for necrotic tissues have emerged as 
a potential option for medical applications. These so called 
necrosis avid contrast agents (NACAs) include paramagnetic 
metalloporphyrins such as bis-gadolinium-diethylene tria-
mine pentaacetic acid (Gd-DTPA) mesoporphyrin 
(gadophrin-2) and manganese tetraphenylporphyrin (Mn-
TPP) [3-5] as well as nonporphyrin agents such as bis-Gd-
DTPA-pamoic acid bis-hydrazide (ECIII-60) and bis-Gd-
DTPA-benzylidene-bis-indole (ECIV-7) [3, 4, 6]. In cardiol-
ogy, the use of these NACAs may provide early localization 
and depiction of myocardial infarction (MI), patient follow-
up, outcome assessment of revascularization therapies [7] 
and detection of many others cardiac complications and pa-
thologies [8-10]. By using optical imaging, the fluorescent  
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probe hypericin has shown its favorable features for the 
visualization of MI [11]. In nuclear imaging, diverse “hot 
spot” imaging tracers with affinity for necrosis have been 
also tested for MI visualization such as technetium-99m 
based agents [12, 13], indium-111 labeled antimyosin anti-
bodies [14] and the naphthodianthrone hypericin labeled 
with iodine-123 [15].  
In oncology, a generic and unconventional therapeutic 
strategy known as OncoCiDia based on necrosis-avidity has 
recently developed as a complementary approach to improve 
cancer treatment [16, 17]. Contrary to other targeted cancer 
therapies directly hitting mutant and resistant tumor cells, 
OncoCiDia may selectively treat solid cancers by largely 
eradicating the tumor mass plus radioactively cleansing their 
microenvironments. It involves two sequential complemen-
tary procedures: first a vascular disrupting agent (VDA) [18] 
is intravenously administered, which is followed by systemic 
targeted radiotherapy (STR) using a necrosis avid compound 
(NAC) hypericin labeled with iodine-131 (131I-Hyp). Onco-
CiDia is meant for managing cancer (Onco) with both tu-
moricidal (Ci) and diagnostic (Dia) effects. Proof-of-principle 
studies suggest that this unique approach may provide a sim-
ple, practical, reliable and broad-spectrum solution for treat-
ing diverse solid cancers [16, 17]. In the meantime, the 
gamma rays emitted by iodine-131 (131I) allow tumor imaging 
and therapy follow-up. Thus OncoCiDia constitutes a simul-
taneous dual targeting theragnostic anticancer modality.  
In this review article, the current concept of necrosis and 
applicability of necrosis as a target for medical diagnostic 
and therapeutic utilities are discussed (Fig. 1).  
2. BASIC CONCEPTS OF NECROSIS 
2.1. Definition and Etiology  
Necrosis or type-III cell death is defined as the part of 
tissue death in a living body. Necrosis has been historically 
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Fig. (1). Flow diagram of the included research topics. DNA: deoxyribonucleic acid, Magnevist®: gadolinium-diethylene triaminepentaacetic 
acid, Dotarem®: gadolinium-tetraazacyclododecanetetraacetic acid, Gadophrin-2; ECIII-60: bis-Gd- N, N'-bis(diethylenetriaminopentaacetato)-
4,4'-methylene-bis (2-hydroxy-3-naphthoic hydrazide); ECIV-7: bis-Gd- N,N'-bis(diethylenetriamine pentaacetic acid)-3,3'-(benzylidene)-bis-
(1H-indole-2-carbohydrazide); MultiHance®: gadobenate dimeglumine, Magnevist®: gadopentetate dimeglumine, MoAb: monoclonal anti-
bodies, Primovist®: gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid; Telescan®: manganese - N, N'-dipyridoxylethylenediamine-
N, N'-diacetate-5, 5'-bis(phosphate), TNT: tumor necrosis treatment, 99mTc: technetium, 111In: indium-111, 123I: iodine-123, 131I: iodine-131. 
 
considered as a non-programmed, non-physiological process 
caused by physicochemical stimuli and/or genetically pro-
grammed injuries (Fig. 2) [2]. Extreme radiation exposure 
and abnormal temperatures (e.g. < 0°C and > 60°C), high 
concentrations of chemicals (e.g. toxins, insecticides, and 
ethanol), oxygen deprivation (e.g. hypoxia and ischemia) and 
nutritional imbalance can induce necrosis [2]. Genetic reac-
tions and infectious agents (e.g. bacteria, viruses and fungi) 
have been identified as necrotic pathogens. Neurodegenera-
tive syndromes and pathologies, such as Huntington’s dis-
ease, Parkinson’s disease, and amyotrophic lateral sclerosis 
[19], may also involve necrosis.  
Contrary to apoptosis, which has been identified as an 
evolutionarily conserved programmed multi-pathway cell-
death, necrosis has been stereotyped as an unregulated proc-
ess [20]. However, recent studies have shown the existence 
of multiple pathways of a regulated necrotic process, also 
known as necroptosis. Examples are mitochondrial perme-
ability transition (MPT), poly (adenosine diphosphate-
ribose) polymerase 1 (PARP1) hyperactivation, the necro-
some, the system cysteine (Cys)-glutamate antiporter, nicoti-
namide adenine dinucleotide phosphate-oxidase (NADPH) 
and the inflammasome [21, 22]. Various necroptosis induc-
tors have been also identified including tumor-necrosis factor 
(TNF), caspase-8 mutations [23], CD95 (Fas/APO-1)-ligand  
 
(CD95L), TNF-related weak inducer of apoptosis 
(TWEAK), TNF-related apoptosis-inducing ligand (TRAIL), 
genotoxic stresses and certain anticancer drugs. Pathogen-
associated molecular patterns (PAMPs), lipopolysaccharide-
mediated activation of Toll-like receptor 4 (TLR4), retinoic 
acid inducible gene I (RIG I)-like receptors (RLRs), and re-
cently, interferons (IFNs) have also shown their necroptosis 
inducing activities [22]. Regarding the cell death-upstream 
regulators, unlike apoptosis which is typically mediated by 
caspase cascade, the necroptotic process does not depend on 
caspase activity, but on the kinase activity. The involvement 
of receptor-interacting protein kinase 1 (RIPK1)- and 
RIPK3-mixed lineage kinase domain-like protein (MLKL) 
has been identified as the major feature of the necroptotic 
death pathway [22]. However, recent studies have also re-
vealed emerging regulatory mechanisms such as NETosis, 
oxytosis, pyronecrosis, ferroptosis and parthanatos that are 
reported to come about either independently of RIPK1 or 
RIPK3 or in the presence of RIPK1 or RIPK3 inhibitors 
(Fig. 2) [22].  
2.2. Pathophysiological Features  
Necrosis is morphologically characterized by cytoplas-
mic granulation, nuclear changes, organelle and/or cellular 
swelling ‘oncosis’, plasma membrane rupture and leakage of 
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Fig. (2). Simplified scheme of the etiology and morphology of necrosis. Many physicochemical and pathological triggers are involved in the 
initiation of the necrosis that was initially considered as a uniquely unregulated process. Necroptosis is a form of regulated cell death that can 
be caused by diverse biochemical stimuli, such as tumor necrosis factor (TNF), CD95L, TNF-related apoptosis-inducing ligand (TRAIL), 
interferons (IFNs), lipopolysaccharide (LPS) and TNF-related weak inducer of apoptosis (TWEAK), caspase-8 inactivation, genotoxic stress 
and anticancer drugs. Upon activation, the necroptotic process is driven by receptor-interacting protein kinase 1 and 3 (RIPK1/3). Additional 
regulator pathways including NETosis, oxytosis, pyronecrosis, ferroptosis and parthanatos have been recently identified. From the morpho-
logical point of view, both necrosis and necroptosis share similar features distinguished by oncosis, nuclear changes, plasma membrane col-
lapse and inflammation. 
 
intracellular content (Fig. 2) [1]. Although necroptotic cell 
death comes about under regulated conditions, both necrop-
tosis and unregulated necrotic death share similar morpho-
logical features distinguished by irreversible changes in the 
cytoplasm and nucleus of the dead or dying cells [24].  
Necrotic cells typically exhibit high levels of eosinophilia 
due to an increase in the binding of eosin to denatured cyto-
plasmic proteins and the occurrence of the cytoplasmic 
RNA-associated basophilia. By electron microscopy, the 
morphology of dead cells can be clearly distinguished by 
ruptures in plasma and membranes surrounding the organ-
elles, dilated mitochondrias resembling large amorphous 
densities, intracytoplasmic myelin figures, unstructured os-
miophilic remnants and fluffy material [2]. Eventually, these 
structures are phagocytosed by other cells or converted into 
fatty acids whose further calcification contributes to a cal-
cium soap formation [25]. Microscopic observations have 
shown significant nuclear modifications eventually leading 
to nuclei dissolution within two days [2]. Dissociation of 
ribosomes from the endoplasmic reticulum as well as nu-
cleus disintegration with chromatin condensation due to nu-
cleus dissolution (karyolysis), nuclear shrinkage/condensa- 
tion accompanied with an increase of basophilos (pyknosis) 
and nucleus rupture (karyorrhexis) occurs [26]. The dead 
cells eventually fade away because of the combination of 
enzymatic denaturation and fragmentation process, followed 
by polymorphonuclear leukocyte phagocytosis of solid parti-
cles. Ultimately, the tissue re-grows and the lesion is re-
paired by regeneration and/or scar formation.  
The development of necrotic process requires hours to 
show detectable alteration at cellular level. Cardiac-specific 
enzymatic and protein materials from necrotic muscle pre-
sent in the blood can be detected 2 h after myocardial cell 
death. In a lethal myocardial infarct where the only patho-
logical indication might be occlusion of a coronary artery, 
the initial histological evidence of myocardial necrosis is not 
detectable until 4-12 h later [27]. 
 At early stages of the necrotic process, however, the 
permeability of plasmalemma allows small charged mole-
cules that normally do not pass through the plasma mem-
brane to enter into the cell [26]. These features permit the 
use of cell-impermeable dyes for optical imaging of dead or 
dying cells in tissue cultures. For these purposes, different 
fluorochrome probes have been used such as propidium io-
dide (PI), ethidium homodimer-1 (EthD-1), mono- and di-
meric cyanine nucleic acids, given their reliability and repro-
ducibility [28-30]. These dyes are basically non-fluorescent 
in aqueous solution, however show significant enhancement 
of their fluorescence quantum yield after binding nucleic 
acids. In addition, double staining with two targeting probes 
has been applied for discrimination between apoptotic and 
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necrotic cells in culture tissues [31]. A commercial kit based 
on fluorescent Annexin V and PI is currently available, in 
which Annexin V-positive/PI-negative staining is considered 
as apoptosis and PI-positive staining as necrosis [32]. Dual 
targeting LIVE/DEAD kits containing PI and membrane-
permeant fluorescent probes such as carboxyfluorescein di-
acetate succinimidyl ester (CFDA-SE), Hoechst-33342, 
SYBR-14, 4',6-diamidino-2-phenylindole (DAPI) and acri-
dine orange have been also introduced for viability assess-
ment [33, 34], providing a rapid and convenient assay based 
on fluorescent detection. The simultaneous use of these dyes 
provides a staining pattern which makes it possible to differ-
entiate normal, apoptotic, and dead cell populations. 
Like the necrotizing process itself, the scientific insight 
into this pathology is still expanding and evolving with new 
potential medicinal applications constantly explored as de-
tailed in the following sections.  
3. NECROSIS TARGETING AS BIOLOGICAL PLAT-
FORM OF DIFFERENT IMAGING TOOLS  
Myocardial infarction (MI) is a leading cause of adult 
mortality and morbidity in developed countries [35]. It usu-
ally takes place when the fibrous cap overlying an athero-
sclerotic plaque in a coronary artery breaks apart. The blood 
exposed to the atherosclerotic material coagulates forming 
thrombus or clot, which block the artery and eventually stops 
the blood flow to a section of the heart muscle [36]. As a 
result of prolonged myocardial ischemia, irreversible injury 
and necrosis of myocardial tissues occur.  
Necrosis imaging might constitute a valuable approach in 
the MI management. The development of specific targeting 
agents with affinity for dead and/or ischemic areas has drawn 
significant attentions. Such compounds may allow early de-
tection, delineation of the infarcted or ischemic area, patient 
follow-up over-time and evaluation of the response to revas-
cularization therapies [7]. Other cardiovascular diseases re-
lated to cardiac cell death could be detected including di-
verse cardiomyopathy [8], myocardial inflammation, acute 
myocarditis [9] and detection of acute or chronic diffuse 
myocardial damage caused by cardiac transplant rejection 
[10] 
3.1. Magnetic Resonance Imaging (MRI) 
3.1.1. Evolution of Contrast Agents (CAs) for Targeting 
Necrosis 
Magnetic Resonance Imaging (MRI) has played an es-
sential role for the localization and assessment of myocardial 
viability. It is a non-invasive diagnostic technique that offers 
excellent quality and high-resolution images. However, its 
relatively low sensitivity in comparison to other techniques 
(e.g. nuclear imaging) has constrained the introduction of 
certain agents with magnetic properties for contrast en-
hancement. Most commonly used contrast agents (CAs) are 
based on the transition metal ions of paramagnetic properties 
including gadolinium (Gd3+) and manganese (Mn2+) ions, 
which own a number of unpaired electron spins in the outer 
electron shells and a relatively long electron-spin relaxation 
time. These compounds interact with adjacent water mole-
cules allowing the enhancement of proton relaxation of the 
hydrogen atoms, and then increasing the contrast among the 
different structures in the body. 
Conventional CAs with “supposed” infarct affinity were 
introduced in order to generate enhanced images and im-
prove the delineation between normal and diseased myocar-
dium [37]. Low molecular weight gadolinium complexes 
such as gadolinium-diethylene triamine pentaacetic acid 
(Gd-DTPA) dimeglumine (Magnevist®, Schering AG, Ber-
lin, Germany) and gadolinium-tetraazacyclododecane 
tetraacetic acid (Gd-DOTA or Dotarem®, Guerbet, France) 
are the most commonly used [38]. However, uncertainties 
were noted due to insufficient discrimination between differ-
ent cardiac diseases, e.g. reversibly versus irreversibly dam-
aged myocardium, acute versus chronic myocardial infarc-
tion (MI), and ischemic versus inflammatory lesions [39]. 
Non-selective enhancement of necrotic tissues, wash-in and 
washout kinetic patterns and main elimination route through 
the kidneys were observed [3]. As a consequence, nephro-
genic fibrosing dermopathy due to the prolonged tissue re-
tention of the bio-incompatible metal gadolinium was clini-
cally confronted in patients with prior renal dysfunction 
when some of such agents are used [40]. Phosphonate-
modified Gd-DTPA complexes were an interesting alterna-
tive characterized by long-term images with high contrast 
enhancement in diffuse and occlusive MI pathologies. They 
interact with calcium-rich tissues causing “in situ” formation 
and precipitation of the insoluble calcium phosphate within 
the injured cardiomyocytes. Nevertheless, overestimation of 
non-viable lesion size due to lack of specificity between 
ischemic and necrotic areas or unwanted effects like cal-
cium-homeostasis disorder and consequently impaired ven-
tricular contractility remain concerns for clinical use [41]. 
A second generation of CAs was developed and nowa-
days are commercially available including manganese - N, 
N'-dipyridoxylethylenediamine-N, N'-diacetate-5, 5'-
bis(phosphate), (Mn-DPDP or Teslascan®; GE Healthcare, 
Milwaukee, WI, USA) [42] gadolinium ethoxybenzyl dieth-
ylenetriaminepentaacetic acid (Gd-EOB-DTPA or Pri-
movist®; Bayer Schering Pharma AG, Berlin, Germany) [43] 
and gadobenate dimeglumine (Gd-BOPTA or MultiHance®; 
Bracco Imaging SpA, Milan, Italy) [44], but they are mainly 
intended for liver imaging due to their major hepatobiliary 
metabolic pathways. 
3.1.2. Necrosis Avid Contrast Agents (NACAs): Structural 
Diversity Versus Common Targetability 
Necrosis avid contrast agents (NACAs) originally repre-
sented a novel group of porphyrin compounds identified by 
Ni et al. [3, 45]. They were conceived as MRI necrosis-
targeting agents to identify acute MI, assess tissue viability, 
and evaluate therapeutic outcomes after interventional treat-
ments. Additional functions like hepatobiliary, adrenal and 
splenic contrast enhancement, first-pass perfusion, blood 
pool contrast effect, and renal functional imaging were also 
demonstrated with NACAs [4, 6]. 
3.1.2.1. Porphyrin-Based NACAs 
Porphyrins are a group of organic compounds found in 
plants and animals as key functional life molecules such as 
hemoglobin, hematoporphyrin, membrane-bound hemopro-
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teins, chlorophylls and cobalamin (vitamin B-12) (Fig. 3). 
Structurally, they are based on an aromatic heterocyclic mac-
rocycle containing four pyrrole moieties coupled by methine 
bridges (=CH-) with a central binding site for metal coordi-
nation (Fig. 3). The extensive conjugation across alternating 
multiple and single bonds amongst adjacent parallel aligned 
p-orbitals of the atoms produce electron delocalization con-
ferring an intense chromaticity, being called “porphyrin”, 
greek term derived from purple. Paramagnetic metallopor-
phyrins are synthesized by means of the coordination with 
transition metal ions such as Gd+3 and Mn+2. 
After multi-institutional reproducibility studies, the Gd-
chelated porphyrin gadophrin-2 ( mesoporphyrin-IX-13,17-
bis(2-oxo-4,7,10,10-tetra(carboxylatomethyl)-1,4,7,10-
tetraazadecyl) diamide, digadolinium complex, disodium 
salt) was accepted as a necrosis targeting MRI contrast agent 
due to its high necrosis-avidity and specific uptake in myo-
cardial infarction [4, 6]. Chemical modifications of 
gadophrin-2 structure by hosting a copper ion into the core 
of the cyclic tetrapyrrole ring lead to gadophrin-3 with supe-
rior structural stability and safety [46]. However, their com-
mercial introduction was abandoned by the pharmaceutical 
companies due to their presumed clinical intolerance and 
unwanted effects related to the chemical nature and photo-
toxicity [3].  
3.1.2.2. Non Porphyrin-Based NACAs 
The correlation between the cyclic tetrapyrrole structure 
of porphyrins and targetability was investigated. Four out of 
nine metalloporphyrins lacked of necrosis avidity, suggesting 
the tetrapyrrole ring is unlikely a structural prerequisite for 
the specific targetability [3, 4]. Mono, bis-, and tri-pyrrole 
derivatives as well as open chain tetrapyrroles were evalu-
ated, showing no convincing necrosis-specificity [3]. These 
findings opened the possibilities to generate non-porphyrin 
based NACAs with lighter color and without unwanted side-
effects associated with porphyrin-based compounds. Indeed, 
two potential NACAs, the light yellowish bis-Gd- N, N'-
bis(diethylenetriaminopentaacetato)-4,4'-methylene-bis (2-
hydroxy-3-naphthoic hydrazide) (bis-Gd-DTPA pamoate or 
ECIII-60) and the colorless bis-Gd- N,N'-
bis(diethylenetriamine pentaacetic acid)-3,3'-(benzylidene)-
bis-(1H-indole-2-carbohydrazide) (bis-Gd-DTPA ben-
zylidene-bis-indole or ECIV-7) were synthesized [4, 6] hav-
ing extraordinary necrosis avidity and excellent properties for 
medical purposes (Fig. 4). The former is derived from pamoic 
acid, which is a common matrix for pharmaceutical prepara-
tions [47]. The latter is an indole derivative that partially 
simulates catabolic metabolites of organisms [48]. Unfortu-
nately, after completing the last reserved batch in our recent 
preclinical oncological study [49], non-porphyrin NACAs for 
MRI became momentarily unavailable because of human 
 
Fig. (3). Schematic representation of the typical chemical structure of porphyrin consisting of aromatic heterocyclic compound with four 
pyrrole moieties coupled by methine bridges and a central site for metal coordination. Pophyrin compounds enclose functional life molecules 
such as 7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid (hematoporphyrin), α-(5,6-
dimethylbenzimidazolyl) cobamidcyanide (vitamin B12) and magnesium,[3,7,11,15-tetramethyl-2-hexadecenyl-9-acetyl-14-ethyl-13,14-
dihydro;-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoato(2-)-n23 (bacteriochlorophyll).  
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reasons beyond the authors’ control [49]. Recent efforts seem 
promising to recover them (data to be published).  
In addition to the abovementioned porphyrin and 
nonporphyrin NACAs, there seems to be a wide diversity in 
structures and molecular sizes of synthetic or natural com-
pounds, which share common necrosis avidity [3] and have 
been eventually so-called as necrosis avid compounds 
(NACs). From small molecules like organic dyes or mono-
saccharide derivatives (MW∼500 g/mol) (Table 1) to large-
size monoclonal antibodies fragments (MW∼50 000 g/mol) 
or protein based compounds (Table 2), all they might bind to 
components present in the necrotic debris, such as phosphol-
ipids and protein residues in dead cells (Fig. 5). This wide 
diversity of compounds with apparently different mechanism 
of necrosis targetability has opened up new opportunities 
beyond traditional target-specific agents for diagnosis and/or 
therapy in cardiology and oncology fields (Table 3).  
3.2. Optical Imaging  
Optical imaging (OI) utilizes fluorescent probes and lumi-
nescent labels and has been exploited for identifying necrotic 
tissues. The 1,3,4,6,8,13-hexahydroxy-10,11-dimethylphen-
anthro [1,10,9,8-opqra]perylene-7,14-dione (hypericin) is a 
fluorescent, red-colored anthraquinone-derivative (naphthodi-
anthrone) that can be isolated from the perennial herb Hy-
pericum perforatum L (St. John’s Wort) (Fig. 4) [50] or 
chemically synthesized. Over decades, it has attracted medical 
interests due to its broad spectrum of biological and pharma-
cological properties such as antimicrobial, antiviral, antide-
pressant, antitumor and anti-inflammatory activities [51]. Re-
cently, it has been found with a selective and outstanding af-
finity for necrotic cell debris (Fig. 4) [3, 15]. Although the 
mechanism underlying its necrosis avidity is still unknown, 
several potential binding pathways have been proposed includ-
ing low-density lipoproteins (LDL), albumins and cell mem-
brane lipids such as cholesterol, PE and PS [52]. Upon excita-
tion with specific wavelength of light by lasers such as 488 nm 
(Argon) and 543 nm (Helium-Neon) or by light xenon arc 
lamp at 380-450 nm or 375-400 nm [53], hypericin shows 
very strong fluorescent properties in the orange-red region 
(600–650 nm). By exploiting this feature, it has been recently 
tested as a viability marker in a rat model of MI for its poten-
tial to determine myocardial viability [11].  
 
Fig. (4). Schematic representation of necrosis avid compounds and their selective affinities for necrotic tissues. A1-A3: Ex vivo analysis of 
bis-gadolinium-diethylene triaminepentaacetic acid-pamoic acid bis-hydrazide (ECIII-60) (A1) in a dog with a small acute myocardium in-
farction involving only posterior papillary muscle. The NAC ECIII-60 caused a precise, strong and persistent contrast enhancement on T1-
MRI even 24h after intravenous injection (A2) at a 1.5-T magnet, as proven by TTC histochemical staining (A3). B1-B3: Post-mortem analy-
sis of necrotic and viable hepatic tissues from rats with reperfused partial liver infarction (RPLI) having received the napthrodianthone hy-
pericin (B1). Macroscopic images of 50-µm-thick sections (B2) and histology co-localization (B3) showed the selective affinity of the highly 
fluorescent hypericin for necrotic liver contrary to the low fluorescence found in viable liver. C1-C3: Post-mortem study of necrotic and 
viable tissues from rats with ethanol-induced muscle necrosis pre-injected with Evans blue dye (C1). The necrotic muscle retained Evans 
blue as blue hyper intense areas, with normal muscle without staining (C2), as was confirmed by histology (C3). MI: myocardium infarction, 
VM: viable myocardium, NM: necrotic muscle, M: muscle, NL: necrotic liver, L: liver. 
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Table 1. Examples of small molecule necrosis avid compounds, their molecular weights and chemical structures. 
Small Molecule-NACs MW (g/mol) Chemical Structure 
mesoporphyrin-IX-13,17-bis(2-oxo-4,7,10,10-tetra 
(carboxylatomethyl)-1,4,7,10-tetraazadecyl) diamide, 
digadolinium complex, disodium salt  (Gadophrin-2) 
  
1759.38 
  
  
1,3,4,6,8,13-hexahydroxy-10,11-
dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-
dione (Hypericin) 
  
  
504.4 
 
tetrasodium (6E,6'E)-6,6-[(3,3'-dimethylbiphenyl-4,4'-
diyl)di(1E)hydrazin-2-yl-1-ylidene]bis(4-amino-5-oxo-
5,6-dihydronaphthalene-1,3-disulfonate)  (Evans blue) 
960.82 
 
  
99m technetium- 99m-glucarate 
  
530.15 
 
  
  
Duramycin from Streptoverticillium cinnamoneus 
  
  
2013.28 
 
  
  
4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-
hydroxynaphthalene-2-carboxylic (pamoic acid)  
  
388.87 
 
  
  
3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) 
(bis-indole)  
  
438.0 
  
 
  
MW: molecular weight, NACs: necrosis avid compounds, Ala: alanine, Asn: asparagine, Asp: aspartic acid, Cys: cysteine, Gly: glycine, Gln: glutamine, Lys: 
lysine, Phe: phenylalanine, Pro: proline, Ser: serine, Thr: threonine, Val: valine. 
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Table 2. Examples of protein structure based necrosis avid 
compounds, their molecular weights and schematic 
representation of their chemical structures. 
Protein Structure 
Based- NACs 
MW (g/mol) Chemical Structure 
Imciromab pen-
tetate Fab 
∼50 000 
 
Annexin V 36 000 
 
C2A domain of 
synaptotagmin I 
12 000 
 
Fab: fragment, antigen-binding region of a monoclonal antibody, VH: variable heavy 
chain, VL: variable light chain, S-S: disulfide bridge, MW: molecular weight, NAC: 
necrosis avid compound. 
 
The tetrasodium (6E,6'E)-6,6-[(3,3'-dimethylbiphenyl-
4,4'-diyl)di(1E)hydrazin-2-yl-1-ylidene]bis(4-amino-5-oxo-
5,6-dihydronaphthalene-1,3-disulfonate) (Evans Blue) is a 
blue dye that is produced by reacting 4-(4-Amino-3-
methylphenyl)-2-methylaniline (o-tolidine) with 1-amino-8-
naphthol-2,4-disulfonic acid (Chicago acid) [54]. Over the 
years, it has been used for intravital staining of plasma leak-
age owing to its high affinity to plasma proteins at a molar 
ratio of 10:1 [55]. However, more recently, its affinity for 
cell death has been experimentally evidenced, making it a 
good optical imaging tracer for severe tissues damage (Fig. 
4). Necrotic lesions in skeletal myofibres have been properly 
identified with Evans Blue in a treadmill-exercised mdx 
mouse model of human Duchenne muscular dystrophy by 
three-dimensional optical coherence tomography (3D-OCT) 
[56]. In more recent studies on biodistribution and tumori-
cidal effects of the necrosis avid radioiodinated Hyp in nude 
mice bearing radiation-induced fibrosarcoma (RIF-1) tu-
mors, rats of reperfused liver infarction (RLI) and rats with 
hepatic rhabdomyosarcoma (R1), systemic injections of 
Evans Blue have been administered to assist in distinguish-
ing necrotic areas over viable tissues [57, 58]. A similar ap-
proach was used in a study on identification of critical com-
ponents of myocardial infarction (MI) including area at risk, 
MI-core and salvageable zone in rabbits by cardiac MRI 
[59]. 
3.3. Nuclear Imaging  
Nuclear scintigraphy presents the most sensitive diagnos-
tic imaging techniques. It uses radiolabelled tracers or com-
pounds recognizing specific structures, receptors or antigens 
to scrutinize the molecular process under in vivo conditions 
in a noninvasive manner. A wide diversity of “hot spot” 
NACs have been exploited for the visualization of myocar-
dial infarction (MI) by nuclear imaging techniques such as 
positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT). 
3.3.1. Necrosis Avid Tracers 
3.3.1.1. Small Molecule - NACs 
The first agent used, technetium-99m (99mTc)-
pyrophosphate, concentrated in necrotic myocardium by 
targeting the calcium phosphate present in the mitochondria 
of infarcted or harshly damaged myocardium [13]. Neverthe-
less, its poor specificity for distinguishing ischemic and
 
Fig. (5). Three-dimensional representation of examples of necrosis avid contrast agents such as a monoclonal antibody, a protein domain, the 
naphtodianthrone hypericin and the 99mTc-labeled glucarate, showing their wide diversity in structure and molecular size. 
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Table 3. Examples of necrosis avid compounds, their proposed interaction mechanism and potential clinic applications. 
Necrosis Avid Compounds (NACs) Proposed Mechanism Applications and Potentialities 
Small molecule - NACs   
Gd-chelated porphyrin gadophrin-2 plasma albumin MI detection with MRI 
Hypericin 
low-density lipoproteins, albumin, 
cholesterol, PE and PS 
MI detection or therapeutic evaluation after interventional therapies 
with SPECT using 123I-hypericin. 
Treatment of solid tumors using 131I-hypericin 
Sennidin A cell debris 
Therapeutic evaluation after interventional therapies using 123I- Sen-
nidin A 
Evans blue albumin 
Optical imaging of dead tissues in pre-clinical studies like identifica-
tion of area at risk in MI, MI-core and salvageable zone 
99m Tc-glucarate protein histones in denatured nuclei MI detection with MRI 
Duramycin (DUR) PE MI detection with SPECT using 99mTc-HYNIC-DUR 
Pamoic acid (PA) 
exposed intracellular protein in dam-
aged cell membrane 
MI detection with SPECT, PET and MRI using radiolabeled and Gd 
(III)-DOTA/DTPA-PA derivatives 
bis-indole (BI) intracellular debris after cell damage 
MI detection with SPECT, PET and MRI using radiolabeled and Gd 
(III)-DOTA/DTPA- BI derivatives 
Protein structure based-NACs   
Imciromab pentetate Fab cardiac myosin of damaged cells 
MI detection with SPECT with 111In and 99mTc-labelled imciromab 
pentetate 
Annexin V PS 
MI detection with SPECT and PET using radiolabeled annexin V 
derivatives 
C2A domain of synaptotagmin I (C2A) PS MI detection with SPECT with 99mTc-labelled C2A 
DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DTPA: diethylene triamine pentaacetic acid, Gd: gadolinium, HYNIC: hydrazinonicotinamide, 111In-indium-111, 
MI: myocardial infarction, MRI: magnetic resonance imaging, PE: phosphatidylethanolamine, PS: phosphatidylserine, PET: Positron emission tomography, SPECT: Single-photon 
emission computed tomography, 99mTc-Technetium-99m 
 
necrotic tissues [60] might cause overestimation of the in-
farct size [61]. Also, its low in vivo stability led to the release 
and circulation of free pertechnetate and eventually reduced 
diagnostic accuracy and low target-to-background ratio on 
scintigraphic images [15]. 
Glucaric acid or glucarate is a 6-carbon dicarboxylic acid 
obtained from the oxidation of glucose with nitric acid. The 
formed complex between glucarate and 99mTc (Fig. 5) has 
been tested as a necrosis-seeking agent owing to its preferen-
tial accumulation into basic protein histones within dena-
tured nuclei and subcellular organelles in the dead cardio-
myocytes [13]. It shows fast blood clearance, low toxicity 
and low antigenicity, making it an attractive diagnostic agent 
for irreversible injury in myocardium. However, 99mTc-
glucarate only accumulates at early stages of tissue damages 
because of the prompt histone degradation [15]. 
Duramycin is a tetracyclic 19–amino acid peptide pro-
duced by Streptoverticillium cinnamoneus [62]. DUR has a 
3-dimensional lipophilic binding site through which it binds 
the phosphoaminolipid phosphatidylethanolamine (PE) [62] 
with exclusive specificity and high affinity at a molar ratio of 
1:1 [63]. PE represents around 20% of all phospholipids in 
mammalian cell membranes and, like phosphatidylserine 
(PS), is merely located at the cytosolic side of the cell mem-
brane [64]. In necrosis, PE becomes accessible to the ex-
tracellular surface due to loss of plasma membrane integrity 
that makes it as a potential molecular target for cell death 
imaging. In a former study, promising results were obtained 
by using 99mTc-HYNIC DUR derivative as PE-specific agent 
using an in vivo rat model of myocardial ischemia and reper-
fusion [65]. In a recent report, a 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 
DUR conjugate was synthetized, characterized and labeled 
with 68Ga to develop a cell death biomarker for the highly 
sensitive technique of positron emission tomography (PET) 
imaging. The radiolabelled peptide was assessed by 
liposome- and cell-based assays and in tumor-bearing mice 
undergoing anti-cancer therapy. Overall, promising results 
were obtained for the assessment of therapeutic efficacy in 
rodents, suggesting its potential applicability as preclinical 
candidate for cell death imaging [66]. 
The potential usefulness of radioiodinated hypericin 
(mono-[123I] iodohypericin), a radioactive derivative of the 
potent necrosis avid hypericin has also proved its potential 
for the detection and quantification of acute myocardial in-
farction (MI) in infarcted rabbits by using single-photon 
emission computed tomography (SPECT) imaging (Fig. 6) 
[15, 67], in addition to its oncological applications as de-
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scribed in the next section. In an effort to further enhance the 
biodistribution and clearance properties of the very lipophilic 
radioiodinated hypericin, other derivatives were also devel-
oped by slightly modification of its chemical structure in-
cluding mono-[123I] iodoprotohypericin [68] and mono-
[123I]iodohypericin monocarboxylic acid [69] (Fig. 7). Al-
though these radioiodinated compounds show their suitabil-
ity for the detection of necrotic regions, the radionuclide 
technetium (99mTc) was also considered for hypericin be-
cause of its better availability and lower cost than those of 
123I [70]. By linking hypericin with the bifunctional chelating 
agent, mercaptoacetyldiglycyl-1,5-diaminopentylene, a new 
tracer agent was obtained and then conjugated to the radio-
metal 99mTc (Fig. 7). However, unlike the radioiodinated 
hypericin derivatives, it did not exhibit selective necrosis 
avidity for necrotic regions within subcutaneous RIF-1 tu-
mors from C3H mice. It seems the conjugation of hypericin 
with a 99mTc-chelate, resulting in changes in molecular size, 
electric charge and lipophilic properties, might considerably 
affect the targetability of this tracer agent. Indeed, in a dif-
ferent study, 64Copper (64Cu)-labeled bis-DOTA conjugated 
hypericin (64Cu-bis-DOTA hypericin) was synthesized (Fig. 
7) and used to assess the response of xenograft human 
BT474 breast carcinoma cell tumors in nude mice after being 
treated with photothermal ablation (PTA) therapy in pres-
ence of copper sulfide nanoparticles (CuS NPs). A reduced 
affinity of 64Cu-bis-DOTA hypericin for necrosis in com-
parison with the radiodinated Hyp was also observed [71].  
Similar to hypericin, the abovementioned optical imaging 
tracer EB was previously labeled with 99mTc to be tested as a 
lymphoscintigraphic agent in vivo [72]. Although this appli-
cation is not related with necrosis detection, future studies 
with 99mTc-labeled Evans Blue in animal models of necrosis 
need to be done that might offer an alternative radioactive 
agent for imaging necrosis.  
3.3.1.2. Protein Structure Based-NACs  
Imciromab pentetate (monoclonal antimyosin antibody 
Fab; ∼50 000 g/mol) is a mouse monoclonal antibody anti-
gen binding fragment (Fab) derivative that specifically local-
izes in the intracellular human heavy chain of the exposed 
cardiac myosin of severely damaged cells [13]. After Food 
and Drug Administration (FDA) approval, anti-myosin Fab 
conjugated to diethylene triamine pentaacetic acid (DTPA) 
radiolabeled with Indium-111 (111In) under the name My-
oscint was used in clinic as an imaging agent for the detec-
tion of heart tissue death following MI [73]. Similarly, the 
monoclonal antimyosin antibody linked to 99mTc was also 
tested in patients suffering MI. Safety profile and high sensi-
tivity in imaging detection of both Q-wave and non-Q-wave 
 
Fig. (6). Potential Theragnostic applications by targeting necrosis for cardiology and oncology. A1-A4: Coronal single-photon emission 
computed tomography-computed tomography (SPECT/CT) images of a rabbit with a massive acute MI having received mono-
[123I]iodohypericin (A1). The image shows high radioactivity uptake in the MI along with radioactivity in the blood pool including the left 
ventricular cavity and large blood vessels. Lower uptake in normal myocardium was observed (dashed line delineated dark area & white 
arrow) (A2). A typical autoradiogram of 50-µm-thick sections on short axis cardiac sections corroborates the preferential tracer accumulation 
in dead areas than in normal myocardium (A3)*. Histology analysis confirms the location of the viable myocardium and the infarcted areas 
distinguished by scattered haemorrhage (A4). B1-B4: SPECT, autoradiography and histology of multifocal radiation-induced fibrosarcoma-1 
(RIF-1) from severe combined immunodeficiency (SCID) mice previously injected with CA4P to induce tumor necrosis followed 24h later 
with mono-[131I]iodohypericin. Twelve days after radioactivity administration, a high radioactivity accumulation was seen mostly inside the 
tumor necrosis (yellow arrows). Autoradiograpic (B3)* and histologic (B4) analysis of the tumor after one month of radioactivity injection 
perfectly match with the hotspots on tumors (B2). *Red colour indicates areas with the highest radioactivity accumulation while white repre-
sent the lowest values. MI: myocardium infarction, VM: viable myocardium, NT: necrotic tumour, VT: viable tumour. 
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Fig. (7). Chemical structures of the necrosis avid agent 1,3,4,6,8,13-hexahydroxy-2-[123I]iodo-10,11-dimethylphenanthro[1,10,9,8-
opqra]perylene-7,14-dione (mono-[123I]iodohypericin) (A) and its derivatives including 1,3,4,6,8,15-hexahydroxy-2-[123I]iodo-10,13-
dimethyldibenzo[a,o]perylene-7,16-dione (mono-[123I]iodoprotohypericin) (B), 1,6,8,10,11,13-hexahydroxy-2-[123I]iodo-4-methyl-7,14-
dioxo-7,14-dihydrophenanthro[1,10,9,8-opqra]perylene-3-carboxylic acid (mono-[123I]iodohypericin monocarboxylic acid) (C), technetium-
99m- mercaptoacetyldiglycyl-1,5-diaminopentylene-1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-
dione carboxamide ([99mTc]-hypericin) (D), copper-64-bis-1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid-1,3,4,6,8,13-
hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione ([64Cu]-bis-DOTA-hypericin) (E).  
 
MI even at the early stage were observed [74]. However, the 
commercial production of monoclonal antimyosin antibody 
Fab has been discontinued owing to the reduced number of 
FDA-approved indications, constrained only to the detection 
of ischemic heart disease [15].  
Annexin V is a member of the annexin family of cal-
cium-dependent phospholipid binding proteins and was 
firstly isolated from human placenta. Phosphatidylserine 
(PS) is a negatively charged aminophospholipid typically 
found at the plasma membrane inner leaflet but it becomes 
exposed to the outer surface on apoptotic and necrotic cells. 
Since annexin V specifically binds externalized PS with a 
high affinity (Kd = 7.0 nM) [75], annexin-based radiotracers 
can be used for detection of apoptosis and necrosis. A wide 
variety of annexin V derivatives labeled with different radi-
onuclides such as 99mTc, 111In, iodine-124 (124I), carbon-11 
(11C), gallium-68 (68Ga) and fluorine-18 (18F) have been de-
veloped and pre-clinically evaluated using in vitro platforms 
and/or different animal models [75]. In clinical research, 
however, 99mTc-6-hydrazinopyridine-3-carboxylic acid 
(HYNIC)-annexin V derivatives are the only used so far, 
mainly in patients with ischemia-associated diseases/ condi-
tions and chemotherapy/radiation therapy-induced cell death 
in certain types of cancers [76].  
C2A domain of synaptotagmin I (C2A) is a protein 
mainly located within the synaptic vesicle membranes that 
bind to negatively charged phospholipids, including PS, in a 
Ca2+ ion -dependent manner. In previously reported studies, 
the C2A was fused to glutathione S-transferase and radiola-
belled with 99mTc leading to 99mTc-C2A-GST for imaging of 
cell death in rat and pig models of acute MI [77] or in a 
mouse model of non-small-cell lung carcinoma (NSCLC) 
after paclitaxel chemotherapy [78]. Increased 99mTc-C2A-
GST uptake was seen either in the myocardial infarcts or in 
treatment-induced cell death within NSCLC tumors. Similar 
results were obtained with a fluorine-18 labeled derivative of 
C2A-GST in a rabbit model of lung cancer after paclitaxel 
chemotherapy [79].  
3.3.1.3. Radioactive NACs Based on MRI-NACAs Results 
Based on the previous promising results obtained with 
both bis-Gd-DTPA-pamoic acid bis-hydrazide (ECIII-60) 
and bis-Gd-DTPA- benzylidene-bis-indole (ECIV-7) for 
MRI, a number of radiolabelled derivatives of these com-
pounds were developed.  
Two 99mTc-tricarbonyl complexes of pamoic acid deriva-
tives were synthesized and evaluated in animal models of 
necrosis (Fig. 8). The lipophilic 99mTc-tricarbonyl-[N-(5-
aminopentyl)pyridin-2-yl-methylamino]methylacetato-4,4'-
methylene-2-hydroxy-3-napthalene carboxamide-(2'-
hydroxy-3'-naphthoic acid methyl ester) showed no affinity 
for necrotic tissues and hepatobiliary pathway as main elimi-
nation route. In contrast, the more polar 99mTc-tricarbonyl 
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complexes of N, N'-bis(diethylenetriaminopentaacetato)-4,4'-
methylene bis(2-hydroxy-3-naphthoic hydrazide) 
(99mTc(CO)3-bis-DTPA-pamoate) exhibited affinity and 
specificity for necrotic areas being eliminated via both the 
kidneys and the liver. In a further study, a 68Ga labeled bis-
DTPA-pamoate derivative was developed for in vivo detec-
tion of dead areas (Fig. 8). The presence of acyclic DTPA 
allowed the conjugation of the compound with the generator 
produced positron emitter 68Ga to be used as an imaging 
agent in the highly sensitive PET. However, a limited in vivo 
stability was observed, most likely because DTPA is not an 
appropriate chelator for 68Ga, leading to a distorted organ 
distribution and high blood pool activity [80]. In a later 
study, pamoic acid bis-hydrazide was conjugated to the mac-
rocyclic ligand DOTA to improve the stability and biodis-
tribution with the previous reported bis-DTPA derivate. Af-
ter labeling with 68Ga, the resulting derivative 68Ga-bis-
DOTA-pamoate (Fig. 8) revealed high in vivo stability, se-
lective accumulation in necrotic tissue and a more favorable 
biodistribution [81].  
With benzylidene-bis-indole, a 99mTc-tricarbonyl com-
plex of bis-DTPA derivative was also synthesised (Fig. 9) 
and studied on animal models of necrosis. Results indicated 
that it could selectively concentrate in dead regions. In a 
more recent study, a 68Ga labeled bis-DOTA derivative of 
benzylidene-bis-indole was developed (Fig. 9) and evaluated 
in a mouse model of Fas-mediated hepatic apoptosis in cor-
relation with histochemical stainings. The tracer proved to be 
stable in vivo and selective avidity for necrotic cell death 
[82]. 
The uptake mechanisms underlying these radiolabelled 
compounds in necrotic tissue still remain unknown. A possi-
ble hypothesis suggests that these tracers interact with an 
intracellular protein that is denatured and exposed after the 
loss of the plasma membrane integrity throughout the cell 
death process [81, 82].  
4. TARGETING NECROSIS FOR THERAGNOSTIC 
APPLICATIONS IN ONCOLOGY 
4.1. Cancer Therapies Based on Necrosis 
Cancer is one of the most common global life threats and 
includes a complex group of over 200 malignant diseases 
that can be caused by both genetic and environmental risk 
factors. Over the last decades, an escalated increase in preva-
lence and incidence of cancer has been noticed worldwide. 
 
Fig. (8). Schematic representation of the chemical structures of 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-
carboxylic (pamoic acid) (A) and its derivatives including bis-gadolinium-N,N′-bis(diethylenetriamine pentaacetic acid)-pamoic acid bis-
hydrazide (bis-Gd-bis-DTPA-pamoate) (B); technetium-99m-tricarbonyl-N-(5-aminopentyl) pyridin-2-yl-methylamino] acetato-4,4′-
methylene-2-hydroxy-3 napthalenecarboxamide-(2′-hydroxy-3′ -naphthoic acid methyl ester) (Tc99m (CO)3-pamoate derivative) (C); techne-
tium-99m-tricarbonyl-NN′- bis(diethylenetriamino-pentaacetato)-4,4′-methylene bis(2-hydroxy-3-naphthoic hydrazide (Tc99m (CO)3-bis-
DTPA-pamoate) (D); gallium-68-N,N′-bis(diethylenetriamine pentaacetic acid)-pamoic acid bis-hydrazide ([68Ga]-bis-DTPA-pamoate) (E); 
gallium-68-N,N′-bis(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-4,4′-methylene-bis(2-hydroxy-3-naphthoic hydrazide) 
([68Ga]-bis-DOTA-pamoate) (F).  
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About 20 million new cancer cases [83] and a mortality of 12 
million deaths [84] have been estimated within the upcoming 
two decades. Accordingly, rising costs for diagnosis, treat-
ment and follow-up are expected. While surgical removal 
benefits few patients, radio- and chemo-therapies are com-
monly regarded as palliative procedures to delay tumor 
growth and extend patient survival. The development of 
more innovative and cost-effective strategies is essential to 
improve cancer management. 
Systemic targeted radiotherapy (STR) is an evolving 
modality that uses systemically administered radioactive 
agents to preferentially deliver alpha or beta radiation doses 
to cancer cells while sparing normal tissues. As clinical 
therapeutic agents, radioiodine for thyroid cancer [85]; 
metaiodobenzylguanidine labeled to iodine-131 (131I) in the 
treatment of adrenal medullae tumors [86]; glass radioactive 
microspheres containing yttrium-90 (90Y) for targeted liver 
cancer therapy [87]; rhenium-186-1, 1-hydroxyethyli-
denediphosphonate (186Re-HEDP), strontium-89 chloride 
(Metastron) and Samarium-153 ethylene diamine 
tetramethylene phosphonate (153Sm- EDTMP, lexidronam) 
to relieve pain in patients suffering bone metastases [88, 89] 
have been used. Anti-CD20 monoclonal antibody (MoAb) 
labeled with either 131I (tositumomab, Bexxar®) [90] or 90Y 
(ibritumomab tiuxetan, Zevalin®) [91] for refrac-
tory/resistant B-cell non-Hodgkin lymphomas as well as 
lutetium-177 or 90Y-labeled somatostatin analogs for treat-
ing neuroendocrine tumors [92, 93] were also introduced. 
More recently, radium-223 chloride (223Ra; Alpharadin) was 
developed for castration-resistant prostate cancer patients 
with metastatic bone disease [94]. However, few advances 
have been made to treat the most common solid tumors that 
feature diverse histological patterns, disorganized angio-
genesis [95] and frequent resistance to biology-based thera-
pies due to unpredictable inherent mutations or escaping via 
overlapped molecular pathways [96, 97].  
4.1.1. Tumor Necrosis Treatment (TNT) 
Pursuing to evade inherent mutations and escape mecha-
nisms of cancer cells [96], tumor necrosis treatment (TNT) 
emerged as an innovative anticancer approach that targets 
the necrotic portion of the tumor [98]. As the proportion of 
dead cells in tumors can account for above 50% of the total 
cancer cell population [99], TNT uses MoAb linked to ap-
propriate radionuclides [100] or immune activators [101] that 
specifically targets intracellular antigens (DNA-histone 
complex) present in the necrotic tumor areas but absent in 
living tissues. Thence, they kill nearby remnant tumor cells 
via radiation cross-fire effect or by generating antitumor 
immune responses. 
The first TNT antibody developed was a murine TNT-1 
having specificity for DNA-histone 1 complex that showed 
to concentrate specifically to tumor necrotic sites in pre-
clinical and clinical studies [102, 103]. In a breakthrough 
 
Fig. (9). Chemical structures of 3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) (A) and its derivatives including bis-gadollinium-N,N′-
bis(diethylenetriamine pentaacetic acid)-3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) (bis-Gd-bis-DTPA-bis-indole) (B); techne-
tium-99m-tricarbonyl- N,N′-bis(diethylenetriamine pentaacetic acid)-3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) (Tc99m (CO)3-bis-
DTPA-bis-indole) (C); gallium-68-N,N′-bis(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)- 3,3′-(benzylidene)-bis-(1H-indole-2-
carbohydrazide) ([68Ga]-bis-DOTA-bis-indole (D).  
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study, Chen et al. [102] demonstrated the effective and 
preferential targeting of TNT-1 MoAb labeled with iodine-
131 in nude mice bearing ME-180 human cervical carci-
noma. This established the potential clinical usefulness of 
TNT for imaging and therapeutic treatment of cancer. 
Three chimeric TNT MoAbs were further developed in-
cluding chTNT-1, chTNT-2, and chTNT-3 which target 
histone DNA complexes, heterochromatic DNA, and sin-
gle-stranded DNA, respectively [104, 105]. Henceforth, 
over 200 patients have received TNT throughout the world. 
In a phase I study for advanced colon cancer, the admini-
stration of 131I-chTNT-1/B MoAb was well tolerated and 
without evidence of any significant non-hematologic side 
effects, however, none of the patients displayed a complete 
or partial response [106]. Promising therapeutic responses 
were observed, however, in different clinical trials on pa-
tients either with high-grade adult gliomas or advanced 
lung cancer having received regional administration of 131I-
chTNT-1/B MoAb [102, 107]. In a further step, indium-111 
labeled genetically engineered Fab' and F(ab')2 constructs 
of chTNT-3 were evaluated in tumor-bearing mice showing 
faster clearance from body, improved tissue distribution but 
lower tumor accumulation than the intact 111In-labeled 
chTNT-3 MoAb [108]. 
Further different strategies were applied in order to im-
prove the potentialities of the TNT strategy. Necrosis induc-
ing treatments (NITs) as starting complementary techniques 
were used for increasing the amount of TNT MoAb binding-
necrotic sites on the tumor [109]. Another approach was the 
synthesis and preclinical evaluation of biotinylated MoAbs 
with faster whole body clearance times and better biodis-
tribution making them promising candidates for the imaging 
and therapy of cancer [110]. By means of genetic engineer-
ing, TNT-3 antibody was also conjugated to immune activa-
tors such as cytokines, or costimulatory molecules leading to 
fused proteins with superior tumor targeting and immuno-
therapic potential due to the resulting immune reaction in the 
tumor surroundings [102]. In a more recent study, a murine 
TNT-3/CD137L fusion protein was generated, characterized 
and evaluated in a Colon 26 tumor model. This molecule was 
able to induce significant tumor suppression by inducing 
CD8+ T-cell–dependent antitumor responses, which seems 
to be a useful choice for future clinical trials [111]. 
However, substantial progresses of TNT-based modality 
in the clinical practice are far from being achieved. Myelo-
suppression as the main side effect associated to unfavorable 
pharmacokinetic properties of radiolabelled MoAbs is con-
tinuously observed [106].  
4.1.2. OncoCiDia  
OncoCiDia is a broad-spectrum anticancer approach with 
great potential for treating solid malignancies. It refers to a 
small molecule sequential dual-targeting theragnostic strat-
egy (SMSDTT) [16] based on a “soil-to-seeds” principle that 
simultaneously allows cancer treatment and diagnostic imag-
ing [17]. Rather than using radiolabeled MoAb with large 
molecular weight (150 000 g mol-1) and unfavorable phar-
macokinetics, OncoCiDia uses two small compounds (<1 
000 g mol-1) with complementary targetability and synergetic 
tumoricidal efficacy.  
Initially, a vascular disrupting agent (VDA) is given to 
selectively destroy established tumor blood vessels leading 
to intratumoral vascular shutdown and subsequent central 
necrosis. However, a narrow rim of tumor cells always sur-
vives and acts as a germ for tumor repopulation or re-growth 
[18]. Iodine-131 labeled hypericin is then IV administered to 
preferentially concentrate at the freshly produced necrotic 
portion in the tumor, and from there, to eradicate remaining 
tumor cells via radiation crossfire effect (Fig. 6) [16, 17]. 
Because, mono-[131I]iodohypericin has a small molecular 
size it is able to penetrate faster into tissues and reach less 
accessible areas across the solid tumor. This may solve pre-
vious limitations confronted with the systemic delivery of 
large sized MoAbs that generally show poor diffusion and 
distribution through the tumor interstitial space [112]. 
4.1.2.1. Vascular Disrupting Agents (VDAs)  
Vascular disrupting agents (VDAs) are a group of tar-
geted anticancer agents that have been known to synergisti-
cally improve radiation, chemotherapy or thermal treatments 
of solid malignancies. It is well known that intact and func-
tioning blood vessels are essential for cancer cell growth and 
survival. It has been also reported that blood vasculature in 
tumors proliferate more rapidly than those in normal tissues 
[17]. VDAs selectively affect established but fragile vascular 
network of large solid tumors to trigger vascular shutdown 
by rapidly destroying tubulin cytoskeleton in the endothe-
lium. Newly formed endothelial cells are more sensitive than 
mature ones that own well developed actin cytoskeleton and 
may retain the cell shape in spite of depolymerization of the 
tubulin cytoskeleton by the VDAs [113]. After VDA admini-
stration, the occlusion of blood vessels and capillary sprouts 
obstructs oxygen and nutrient supply to the tumor cells, 
compromising cellular integrity and eventually leading to 
widespread hemorrhagic necrosis at the tumor core [114].  
Two main classes of VDAs have been developed includ-
ing tubulin-binding agents (TBAs) and flavonoids. TBAs 
cause microtubule depolymerization by binding either the β-
subunit of endothelial tubulin of colchicine sites or by dis-
rupting the VE-cadherin/β-catenin complex which interfere 
with cell–cell contact [115]. Flavonoids derivatives, instead, 
do not accumulate in tumor-related vasculature, but selec-
tively obstruct blood vessels due to their pharmacodynamics 
effect such as platelet release due to flavonoid associated-
DNA damage to endothelial cells [116]. VDAs can be ob-
tained from natural products such as combretastatins (CA4P, 
OXi-4503, and AVE-8062), colchicines (ZD6126) and 
phenylahistin (NPI-2358), whilst others are synthetic com-
pounds (DMXAA, MN-029 and EPC2407) [114].  
However the toxicity of VDAs has prevented their use-
fulness in the clinical setting. So far VDAs with lower toxic 
effects have been recently developed by conjugating them to 
other molecules such as polyethylene glycol, CNGRCG pep-
tide or nanoparticles (liposomes, gold) [117]. Regarding 
treatment efficacy, VDAs have shown limited effectiveness 
in achieving prolonged antitumor effects [118]. This has 
been partially related to a ‘vascular rebound effect’ in which 
the rims of tumours are more treatment resistant, and can 
serve as a seed for revascularization and re-population. 
Therefore, the anticancer effect of VDAs might be enhanced 
by their combination with other therapeutic modalities such 
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as radiotherapy, antioangiogenic therapy or chemotherapy 
[119, 120]. In case of OncoCiDia in which necrosis act as a 
magnet that attracts the radioactive drugs towards the tumor, 
alternative necrosis inducing treatments (NITs) can be used 
mainly in small tumors (< 5 mm), which receive oxygen and 
nutrients by diffusion from the adjacent tissue [121]. 
4.1.2.2. Alternative Necrosis Inducing Treatment (NIT) for 
OncoCiDia 
NITs have been developed for treating oncologic patients 
with tumor recurrences or those who cannot endure conven-
tional surgical resection. NITs are designed to destroy ma-
lignant tissues with a minor damage to adjacent normal tis-
sues. Low cost, reduced morbidity and outpatient utilization 
make them as attractive therapeutic modalities. 
Radiofrequency ablation (RFA) causes cell death using 
heat generated from the high frequency alternating current in 
the radio-frequency range (460-500 kHz). The ionic agitation 
in the adjacent tissue produces frictional heat that spreads 
outwardly from the electrode by conduction [122]. Micro-
wave ablation (MWA) makes use of microwaves to induce 
an ultra-high-speed (2450 MHz) alternating electric field, 
which causes the rotation of water molecules [123]. Unlike 
RFA, MWA does not contain retractable prongs and does not 
need a ground pad [124]. Laser interstitial thermotherapy 
(LITT) often applies a neodymium yttrium aluminum garnet 
(Nd-YAG) laser to deliver high-energy light to the target 
lesion. Once the light is spread within the tissue, it is con-
verted into heat energy [124]. Unlike RFA, MWA and LITT, 
cryoablation delivers subfreezing temperatures using probes 
through which a cryogen is circulated [124]. Percutaneous 
ethanol injection (PEI) is the simplest, costless technique and 
requires minimal equipment. By injecting absolute alcohol 
through a percutaneously placed needle directly into a tumor, 
cellular dehydration and tissue ischemia from vascular 
thrombosis occur [125], resulting in chemically induced tu-
mor coagulation necrosis. 
4.1.2.3. Iodine-131 Labeled Hypericin (mono-
[131I]iodohypericin) 
Iodine-131 labeled hypericin (mono-[131I]iodohypericin) 
can be obtained by electrophilic substitution of iodine-131 
(131I) onto the necrosis avid hypericin using mild oxidants 
such as 1,3,4,6-tetrachloro- 3α, 6α -diphenyl glycoluril (Io-
dogen) [126]. It is a simple and rapid (< 30 min) method, in 
which one of the hydrogen atoms on the hydroxyl, aromatic 
ring of hypericin is substituted with an in situ formed, posi-
tively charged 131I atom. Since 131I-Hyp can be produced 
with high labeling efficiency (> 95%), it can be directly used 
in vivo without further purification steps [127].  
In particular, the radionuclide 131I is used as an ionizing 
radiation source due to its proper physical properties. It is a 
beta-emitter that has been commonly exploited for treating 
thyroid cancer due to its native affinity to thyroid tissues as 
well as relatively easy availability and low cost. Because its 
mode of radioactive decay with a half-life of 8.02 days and a 
maximum beta energy of 606 keV (abundance: 89.6%), 131I 
radiation produces DNA damage and death of cancer cells 
containing it (self-dose effect) or being at a distance of some 
millimeters (crossfire effect). Indeed, its tissue penetration of 
0.6-2.0 mm [128] allows to radioactively annihilate the re-
sidual viable tumor rim, left after CA4P treatment, which 
typically has a thickness < 100 µm, being well within the 
irradiation range of the beta particles [58].  
In preclinical studies, mono-[131I]iodohypericin has re-
petitively exhibited high avidity for and long-term retention 
in necrotic tissues (Fig. 5) as well as favorable safety profiles 
in vivo [129, 130]. In radionuclide dosimetry studies, mono-
[131I]iodohypericin has shown uniquely high absorbed radia-
tion doses in necrotic tumor [131], which appeared to be 
superior by far to the values reported for other radiotherapeu-
tic agents commercially available or under preclinical inves-
tigations [102, 132, 133]. Moreover, since OncoCiDia pro-
poses a sequential administration of two compounds with 
high, different but complementary targetability, special at-
tentions were also given to evaluate the role of the combina-
tion of the VDA treatment and mono-[131I]iodohypericin 
administration. Overall, tumor eradication was not achieved 
by injecting either VDA or 131I-hypericin alone. This might 
be explained by the rapid repopulation of the remaining tu-
mor cells after a single attack with VDA alone. Or with 
mono-[131I]iodohypericin alone, it might be due to the lack of 
enough necrotic tumor sites as targeting platform for achiev-
ing high concentrations of mono-[131I]iodohypericin whose 
radiation eventually induces the tumor cell death. It could 
explain the encouraging therapeutic effects observed after a 
single treatment with OncoCiDia. In fact, either noticeable 
shrinkage and significant growth delay in tumor or pro-
longed survival have been reported in rodents with different 
allograft tumors being previously treated by the synergetic 
combination of CA4P and mono-[131I]iodohypericin [16, 58, 
134]. Based on these experimental results, this dual-targeting 
approach appears to be a simple and feasible solution for 
cancer therapy.  
4.1.2.4. Iodine-131 Labeled Sennidin A (monoiodo[131I]-
sennindin A) 
Because hypericin and its radioiodinated derivatives 
show poor water solubility leading to the formation of ag-
gregates [135], which are sequestered into the lung macro-
phages reducing the accumulation of the radiotherapeutic in 
the necrotic tumor and then impairing its therapeutic effects 
[129, 136], new alternatives have been explored. Ji et al. 
[137] reported that a radioiodinated derivative of sennidin A, 
a naturally occurring product originally from the Cassia L. 
Senna plant, could be a good candidate for OncoCiDia [138]. 
Although sennidin A has a similar skeleton to hypericin with 
a condensation of two molecules of anthraquinone, it has 
more free rotation around the single connecting bond be-
tween anthraquinone units. This might allow the sennidin A 
adopts a spatial arrangement for preventing steric hindrance 
[137]. This feature could have an important impact on the 
water solubility of the molecule reducing the formation of 
aggregations in vivo [137] (Fig. 10). Studies on biodistribu-
tion and therapeutic effects of 131I-sennindin A were con-
ducted on S180 tumor-bearing mice prior treated with CA4P 
to cause tumor necrosis. Results revealed high accumulation 
and persistent retention of the radioiodinated compound in 
necrotic tumors and rapid clearance from most normal or-
gans. Synergetic tumoricidal effects such as tumor growth 
inhibition, prolonged tumor doubling time and extended 
mean animal survival were consistently observed [137]. 
1844    Current Medicinal Chemistry, 2015, Vol. 22, No. 15 Cona et al. 
 
Fig. (10). Bi- and three-dimensional representation of the chemical structures of the mono-[131I]iodohypericin (A) and the mono[131I]- io-
dosennindin A (B). Both compounds have similar skeleton characterized by the condensation of two anthraquinone molecules. Contrary to 
the radioiodinated hypericin, the sennidin A derivative has a single connecting bond between anthraquinone units that allows the molecule to 
better accommodate in a spatial arrangement for preventing steric effects. 
 
However, contrary to radioiodinated hypericin, the less lipo-
philic monoiodo[131I]-sennindin A appeared to be highly 
retained by and excreted through kidneys [137]. This bio-
logical profile might lead to acute radiation nephropathy, 
which has been described as a limiting factor for many other 
radiotherapeutic agents [139].  
5. CONCLUSION 
Necrosis is not only a deleterious process in the living 
body as a response to severe stimuli. Targeting necrosis may 
offer new opportunities for innumerable diagnosis and treat-
ment applications in diverse diseases. The clinical introduc-
tion of necrosis avid agents for optical imaging, magnetic 
resonance imaging or nuclear imaging may play a comple-
mentary role in detection and quantification of acute myo-
cardial infarction and in treatment follow-up. On the other 
hand, the use of alpha or beta emitter having high affinity for 
necrotic tissues might play a protagonist role in treat-
ing/curing cancer or prolonging the survival of oncologic 
patients with improved life quality. OncoCiDia is an uncon-
ventional but pan-cancer approach based on the necrosis 
avidity for managing multifocal and multitype malignant 
tumors. It sequentially uses a vascular disrupting agent for 
triggering massive tumor necrosis and the necrosis avid io-
dine-131 labeled hypericin to destroy remaining tumor cells.  
LIST OF ABBREVIATIONS 
11C = Carbon-11 
18F = Fluorine-18 
64Cu = Copper-64 
68Ga = Gallium-68 
90Y = Yttrium-90 
99mTc = Technetium-99m 
111In = Indium-111 
123I = Iodine-123 
mono-[123I]-
iodohypericin 
= Iodine-123 labeled hypericin 
124I = Iodine-124 
131I = Iodine-131 
mono-[131I]-
iodohypericin 
= Iodine-131 labeled hypericin 
131I-MIBG = Iodine-131 labeled metaiodobenzyl-
guanidine 
153Sm-EDTMP = Samarium-153 ethylene diamine 
tetramethylene phosphonate  
177Lu = Lutetium-177  
186Re-HEDP = Rhenium-186-1,1-
hydroxyethylidenediphosphonate 
AVE- 8062 = Ombrabulin 
BMA = Gadolinium- diethylene triamine 
pentaacetic acid- bismethylamide 
CA = Contrast agent 
CA4P = Combretastatin A-4 phosphate 
CE = Contrast enhancement  
DMXAA = 5,6-dimethylxanthenone 4 -acetic acid 
DNA = Deoxyribonucleic acid 
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DUR = Duramicyn 
Evans Blue = Tetrasodium (6E,6'E)-6,6-[(3,3'-
dimethylbiphenyl-4,4'-
diyl)di(1E)hydrazin-2-yl-1-
ylidene]bis(4-amino-5-oxo-5,6-
dihydronaphthalene-1,3-disulfonate 
ECIII-60 = bis-gadolinium- diethylene triamine-
pentaacetic acid-pamoic acid bis-
hydrazide 
ECIV-7 = bis- gadolinium- diethylene tria-
minepentaacetic acid- benzylidene-
bis-indole 
EthD-1 = Ethidium homodimer-1 
EPC2407 = Crolibulin 
Fab = Antibody fragment 
FDA = Food and Drug Administration 
gadophrin-2 = bis-gadolinium diethylene triamine-
pentaacetic acid-mesoporphyrin 
Gd = Gadolinium  
Gd-DTPA = Gadolinium-diethylene triamine pen-
taacetic acid  
Gd-DOTA = Gadolinium-tetraazacyclododecane 
tetraacetic acid 
Gd-EOB-
DTPA  
= Gadolinium-ethoxybenzyl diethylene 
triamine pentaacetic acid 
Gd-BOPTA = Gadobenate dimeglumine  
GST = Glutathione S-transferase 
hypericin  = 1,3,4,6,8,13-hexahydroxy-10,11-
dimethylphenanthro[1,10,9,8-
opqra]perylene-7,14-dione 
HYNIC = 6-hydrazinopyridine-3-carboxylic 
acid 
Iodogen = 1,3,4,6-tetrachloro-3α,6α-diphenyl 
glycoluril 
IFNs = Interferons 
IV = Intravenous 
Kd = Dissociation constant  
LDL = Low-density lipoprotein  
LITT = Laser interstitial thermotherapy  
MI = Myocardial infarction 
MLKL = Mixed lineage kinase domain-like 
protein 
Mn = Manganese  
MN-029 = Denibulin di-hydrochloride 
Mn-DPDP = Dipyridoxyl diphosphate 
MoAb = Monoclonal antibody 
MPT = Mitochondrial permeability transi-
tion 
MRI = Magnetic resonance imaging 
MW = Molecular weight 
MWA = Microwave ablation 
NAC = Necrosis avid compounds 
NACA = Necrosis avid contrast agents 
NADPH = Nicotinamide adenine dinucleotide 
phosphate-oxidase 
NIT = Necrosis inducing treatment 
NPI-2358 = Plinabulin 
NSCLC = Non-small-cell lung carcinoma  
OI = Optical imaging  
OXi-4503 = Combretastatin A1 di-phosphate / 
CA1P 
PARP1 = Poly (adenosine diphosphate-ribose) 
polymerase 1 
PAMPs = Pathogen-associated molecular pat-
terns 
PE = Phosphatidylethanolamine 
PEG400 = Polyethylene glycol 400 
PEI = Percutaneous ethanol injection  
PI = Propidium iodide 
PTA = Photothermal ablation  
PS = Phosphatidylserine 
R1 = Rhabdomyosarcoma 
RFA = Radiofrequency ablation 
RLRs = Retinoic acid inducible gene I 
(RIG-I)-like receptors 
RIP1/3 = Receptor-interacting protein-1/3 
RIF-1 = Radiation-induced fibrosarcoma  
RPLI = Reperfused partial liver infarction 
SMSDTT = Small molecule sequential dual-
targeting theragnostic strategy 
SPECT = Single photon emission computed 
tomography 
STR = Systemic targeted radiotherapy 
TBA = Tubulin binding agents 
3D-OCT = Three-dimensional optical coherence 
tomography  
TNF = Tumor-necrosis factor  
T1 = T1 relaxation time or spin-lattice 
relaxation time 
T2 = T2 relaxation time 
TTC = 2,3,5-Triphenyl-2H-tetrazolium 
chloride 
TNT = Tumor necrosis treatment 
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TLR4 = Toll-like receptor 4 
TRAIL = Tumor necrosis factor -related 
apoptosis-inducing ligand 
TWEAK = Tumor necrosis factor -related weak 
inducer of apoptosis 
VDA = Vascular disrupting agent 
ZD6126 = N-Acetylcolchicinol dihydrogen-
phosphate 
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